A phase 3 trial of SB5, a proposed biosimilar to adalimumab (AbbVie’s Humira), showed that SB5 was equivalent to its reference with respect to the American College of Rheumatology's 20% improvement criteria (ACR20).
A phase 3 trial of SB5, a proposed biosimilar to rheumatoid arthritis (RA) drug adalimumab (AbbVie’s Humira), showed that SB5 was equivalent to its reference with respect to the American College of Rheumatology 20% improvement criteria (ACR20). The results were reported in the January 2018 issue of Arthritis & Rheumatology by Michael E. Weinblatt, MD, and colleagues. The study was funded by Samsung Bioepis, developer of SB5 (brand name, Imraldi).
The double-blind, parallel-group study of patients with moderately to severely active RA despite treatment with methotrexate included 542 patients who were randomized 1:1 to receive SB5 (269 patients) or reference adalimumab (273 patients) at a dosage of 40 mg subcutaneously every other week. The primary efficacy endpoint was response rate based on the ACR20 at week 24. The study also evaluated endpoints of efficacy, pharmacokinetics (PK), safety, and immunogenicity assessments. The study was conducted from May 2014 through May 2015 in 7 countries (Bosnia and Herzegovina, Bulgaria, Czech Republic, Lithuania, Poland, Republic of Korea, and Ukraine).
The investigators found:
The researchers explain that their study was conducted to demonstrate equivalence in terms of clinical efficacy in a representative study population, and was designed to be sensitive enough to detect potential differences in efficacy between SB5 and the reference adalimumab in accordance with European Medicines Agency guidelines. It was not focused on demonstrating efficacy per se, because the efficacy of adalimumab in RA has already been well established. “Examining the efficacy of SB5 in comparison with reference [adalimumab] in RA is an appropriate choice for demonstrating similarity in efficacy between the 2 products,” they note, concluding that their findings showed equivalent efficacy between SB5 and the reference product as demonstrated by the ACR20 response rates and other secondary efficacy endpoints at week 24. “The study demonstrates that SB5 was well tolerated and possessed PK, safety, and immunogenicity profiles comparable to those of the reference [adalimumab].”
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.